RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
TipRanksMay 3 18:43
Strong Financial Growth and Promising Clinical Trials Bolster Buy Rating for Alnylam Pharmaceuticals
TipRanksMay 3 11:45
Alnylam Pharmaceuticals Analyst Ratings
BenzingaMay 3 02:39
Needham: Reiterates Alnylam Pharmaceuticals (ALNY.US) rating and adjusted from buy to buy rating, target price is $200.00.
Zhitong FinanceMay 3 02:40
Wolfe Upgrades Ionis to Outperform, Cites Upcoming Catalysts
Seeking AlphaApr 11 00:03
Alnylam Pharmaceuticals Analyst Ratings
BenzingaMar 27 22:06
Buy Rating Affirmed for Alnylam Pharmaceuticals on Strong Commercial Business and Expanding CNS Pipeline
TipRanksMar 25 18:55
Alnylam Pharmaceuticals Analyst Ratings
BenzingaMar 6 01:03
Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Lowers Price Target to $150
BenzingaFeb 24 01:09
Alnylam Pharmaceuticals Analyst Ratings
BenzingaFeb 24 01:07
RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $235 Price Target
BenzingaFeb 21 22:54
Alnylam Pharmaceuticals Analyst Ratings
BenzingaFeb 21 22:51
RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $235 Price Target
BenzingaFeb 20 23:23
Alnylam Pharmaceuticals Analyst Ratings
BenzingaFeb 20 23:20
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Alnylam Pharma (ALNY) and Catalent (CTLT)
TipRanksFeb 20 20:31
Maintaining Hold on Alnylam Pharmaceuticals Amid Clinical and Financial Uncertainties
TipRanksFeb 19 12:55
Alnylam Pharmaceuticals Analyst Ratings
BenzingaFeb 17 00:51
Chardan Cuts Price Target on Alnylam Pharmaceuticals to $225 From $250, Expects Topline Results in Mid-2024, Maintains Buy Rating
MT NewswiresFeb 16 21:18
Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $225
BenzingaFeb 16 21:14
Alnylam Pharma (ALNY) Was Downgraded to a Hold Rating at Goldman Sachs
TipRanksFeb 16 07:25
No Data
No Data